HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO), which manufactures and distributes a meniscus implant for use in arthroscopic surgery to address the most common form of knee injury, has hired an executive with nearly two decades of orthopaedics experience to lead the company’s surgeon education and training program.